Repligen Corporation $RGEN Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. reduced its holdings in Repligen Corporation (NASDAQ:RGEN) by 1.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,993,945 shares of the biotechnology company’s stock after selling 50,246 shares during the quarter. Vanguard Group Inc. owned 0.09% of Repligen worth $818,308,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Sava Infond d.o.o. increased its position in Repligen by 500.0% in the 4th quarter. Sava Infond d.o.o. now owns 1,200 shares of the biotechnology company’s stock valued at $197,000 after acquiring an additional 1,000 shares during the period. M&T Bank Corp acquired a new stake in Repligen in the 4th quarter valued at approximately $29,819,000. Bayforest Capital Ltd acquired a new stake in Repligen in the 4th quarter valued at approximately $32,000. CWM LLC increased its position in Repligen by 182.7% in the 4th quarter. CWM LLC now owns 950 shares of the biotechnology company’s stock valued at $156,000 after acquiring an additional 614 shares during the period. Finally, Farther Finance Advisors LLC increased its position in Repligen by 61.8% in the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 128 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently commented on RGEN. KeyCorp restated an “overweight” rating on shares of Repligen in a research report on Wednesday, February 25th. Weiss Ratings cut Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, March 3rd. UBS Group lowered their price target on Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Barclays lowered their price target on Repligen from $175.00 to $145.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 14th. Finally, Rothschild & Co Redburn set a $160.00 price target on Repligen and gave the company a “buy” rating in a research report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $170.25.

Repligen Stock Down 0.9%

Shares of RGEN stock opened at $117.20 on Friday. Repligen Corporation has a 1 year low of $109.50 and a 1 year high of $175.77. The stock has a market cap of $6.61 billion, a PE ratio of 137.88, a price-to-earnings-growth ratio of 2.28 and a beta of 1.09. The business’s fifty day moving average is $121.56 and its 200-day moving average is $144.70. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.12 and a current ratio of 8.37.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.05. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The company had revenue of $197.91 million for the quarter, compared to analysts’ expectations of $192.23 million. During the same period last year, the firm earned $0.44 EPS. The firm’s revenue for the quarter was up 18.1% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Equities analysts expect that Repligen Corporation will post 1.97 earnings per share for the current fiscal year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.